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Abstract
Background: We recently reported that estrogen receptor a (ERa), even in absence of estrogen (E2), plays a critical role in
lactotroph homeostasis. The anti-estrogen ICI 182780 (ICI), but not tamoxifen or raloxifene, rapidly promoted the
degradation of ERa, and inhibited cell proliferation. However, all three ER antagonists suppressed PRL release, suggesting
that receptor occupation is sufficient to inhibit prl gene expression whereas receptor degradation is required to suppress
lactotroph proliferation. In this study our objective was to determine whether ERa degradation versus occupation,
differentially modulates the biological outcome of anti-estrogens.
Principal Findings: Using the rat lactotroph cell line, GH3 cells, we report that ICI induced proteosome mediated
degradation of ERa. In contrast, an ERa specific antagonist, MPP, that does not promote degradation of ERa, did not inhibit
cell proliferation. Further, ICI, but not MPP, abolished anchorage independent growth of GH3 cells. Yet, both ICI and MPP
were equally effective in suppressing prl expression and release, as well as ERE-mediated transcriptional activity.
Conclusion: Taken together, our results demonstrate that in lactotrophs, ERa degradation results in decreased cell
proliferation, whereas ERa occupation by an antagonist that does not promote degradation of ERa is sufficient to inhibit prl
expression.
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Introduction
Drugs that block estrogen receptor (ER) activation/function are
categorized as anti-estrogens. Within this class of pharmacological
agents are the selective ER modulators (SERMs) exemplified by
tamoxifene (Tam) and raloxifene (Ral), selective ER down-
regulators, (SERDs) exemplified by ICI 182780 (ICI), and
aromatase inhibitors, which inhibit the conversion of androgens
to estrogens and block ER activation. Since ICI is deprived of any
estrogenic activity [1] it is considered a ‘‘pure’’ anti-estrogen.
Several mechanisms have been proposed to characterize ICI-
mediated ER antagonism. These include competition with ligand
binding to the ER, inhibition of transactivation domains (AF-1 and
AF-2), prevention of ER dimerization and nuclear localization
[2,3], and downregulation of ER [4]. Furthermore, both ERa-
and ERb-mediated transcription is inhibited by ICI, indicating
that both receptor subtypes are targets of ICI [5,6].
A response to estrogen is governed by ER availability. Since the
initial observation of a reduction of ER expression following
exposure to E2 [7], it is now well accepted that the ER protein is
rapidly turned over by both agonist and antagonist and its half life
is reduced from 24 hr to 3–5 hr in the presence of estrogen [8,9].
This degradation of the ER is attributed to the processing of the ER
via the ubiquitin-proteasomal pathway. Blockade of estrogen-
induced ER degradation reduces its transcriptional activity,
suggesting that receptor processing is required for ER function
[10]. The ER is not unique in this respect as other members of the
nuclear receptor super-family also require degradation by ubiquitin-
proteasome for activation [11,12]. To further support this
hypothesis, several proteins (UBC9, RSP5/RPF1, SUG1/TRIP1
and E6-AP) that interact with the nuclear receptors belong to the
ubiquitin-proteasome pathway [13–16]. This suggests that agonist-
mediated ER degradation, although required for transcriptional
activation, could also be a mechanism by which the cell regulates its
responses to estrogens. The pure anti-estrogen ICI also rapidly
degrades the ER via the ubiquitin-proteasome pathway and thus
abolishes the estrogen responsiveness of target cells [4,10].
Interestingly, tamoxifen stabilizes the ER by inhibiting receptor
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importance of regulating the ubiquitin-proteasome pathway, by
both estrogen and anti-estrogens, as a critical process for governing
ER availability, and ultimately its biological outcome.
Lactotrophs are a well established estrogen-responsive cell. Both
genomic and non-genomic effects of E2 have been reported in
lactotrophs. Previous reports showed that ICI suppressed cell
proliferation and affected ER expression in GH3 and PR1 cells
[18,19]. We conducted a detailed comparison of the effects of ICI,
tamoxifen and raloxifene, in the absence of exogenous E2, on
lactotroph proliferation and PRL production/release [20]. We
found that ICI, but not tamoxifen or raloxifene, at low doses
inhibited lactotroph proliferation in an ERa-dependent manner.
The maintenance of basal intracellular PRL levels and PRL
release were dependent on functional ERa. A striking observation
of this study was the very rapid (within 1 hr) reduction in ERa
levels, but a significantly delayed reduction in ERb levels, in
response to ICI. The anti-estrogens, tamoxifen and raloxifene, that
were incapable of inhibiting lactotroph proliferation, did not
downregulate ERa/b [20].
Our objectives in the present study were: first, to determine
whether ICI-mediated ERa degradation or antagonism was
responsible for inhibiting lactotroph proliferation and PRL
expression. Second, to determine whether the disruption of ICI-
mediated ERa degradation reverses the growth inhibition in
lactotrophs. We report that in GH3 cells ERa degradation sets in
motion a signal cascade that culminates in the inhibition of cell
proliferation, while occupation of ERa by an antagonist is
sufficient to inhibit prl expression and release.
Results
Differential effects of ERa antagonists on lactotroph
proliferation
We have recently reported that anti-estrogens had differential
effects on lactotroph proliferation[20]. While tamoxifen and
raloxifene had no growth suppressive effects on lactotroph
proliferation, the pure ER antagonist, ICI, had a potent growth
suppressive effect. We also found that the ability of ICI to suppress
lactotroph proliferation was mediated through ERa [20]. In this
study, we first questioned whether an ERa specific antagonist
mimics the effects of ICI on ERa expression and lactotroph
proliferation.
GH3 cells were treated with either vehicle, ICI (10 nM) or the
ERa specific antagonist MPP (100 nM) [21,22], for 5 days, and
equal amounts of cell lysates were subjected to western blotting
with an anti-ERa specific Ab. Consistent with our previous report
[20], ICI caused a robust degradation of ERa. Unlike ICI, MPP
had no significant effect on ERa levels after 5 days (Fig. 1A).
Next, we questioned whether the rapid downregulation of ERa
levels in GH3 cells by ICI is mediated through the ubiquitin-
proteasome system. Untreated GH3 cells, or cells pretreated with
the broad spectrum proteasome inhibitor MG132 (10 mM, 1 hr),
were incubated with either vehicle or 10 nM ICI for 1 hr, and
equal amount of cell lysate was subjected to western blotting.
Fig. 1B shows that in the absence of MG132, ICI induced a potent
ERa degradation, and this was significantly reversed in the
presence of MG132. Together, these results suggest that ICI
induced degradation of ERa could be the underlying mechanism
for growth suppression.
We next compared the ability of ICI and MPP to suppress GH3
cell proliferation. GH3 cells were treated with either vehicle or the
indicated concentrations of ICI or MPP, and cell proliferation was
determined after 5 days. Fig. 1C clearly demonstrates that
consistent with our previous report, ICI inhibits GH3 cell
proliferation with a maximal inhibitory effect seen at concentra-
tions as low as 1 nM. Conversely, MPP at all tested concentrations
had no significant effect on GH3 cell proliferation.
Since both MPP and ICI competitively inhibit E2 binding to
ER, we questioned whether pretreatment of GH3 cells with MPP
would prevent ICI binding to ERa, thereby blocking its effects. To
address this, we pretreated GH3 cells with excess MPP (100 nM
for 1 hr) and then tested the ability of ICI (1 and 10 nM) to inhibit
cell proliferation. Our results demonstrate (Fig. 1D) that,
pretreatment of GH3 cells with MPP, reversed the inhibitory
effect of ICI on cell proliferation.
ICI 182780 but not MPP inhibits anchorage independent
growth of GH3 cells
We next compared the effects of the ERa antagonists on the
anchorage independent growth of GH3 cells. Our results
demonstrate that GH3 cells have a robust capability to form
colonies in soft agar, and this was significantly decreased by ICI
(Control 100% vs ICI 20.9%) whereas MPP had no effect on
anchorage independent growth of GH3 cells (Fig. 2A and B). The
effects of the anti-estrogens in the anchorage independent growth
assays were similar to those observed in clonogenic assays with
GH3 cells (data not shown).
Both ICI 182780 and MPP are effective at inhibiting PRL
expression as well as suppressing ERE activity
We next examined whether occupation of ERa by an antagonist
or ERa degradation, are required for inhibiting PRL production
and release. We first examined the intracellular levels of PRL in
GH3 cells treated with ICI (10 nM), MPP (100 nM) or
preincubated with MPP for 1 hr, followed by ICI treatment.
Intracellular PRL levels were determined in cell lysates by western
blotting with an anti-PRL Ab. Fig. 3A shows that both ICI and
MPP markedly decreased intracellular PRL levels. Pretreatment
with MPP did not block the ICI-induced decrease in intracellular
PRL, and did not have an additive effect. To further confirm the
suppressive effects of anti-estrogens on intracellular PRL levels, we
used a reporter assay to examine the effects of ICI and MPP on prl
expression. As evident in Fig. 3B, both ICI and MPP suppressed
PRL/Luc activity.
We next examined the effects of the anti-estrogens on PRL
release from GH3 cells. GH3 cells were treated with ICI (10 nM),
MPP (100 nM), or pretreated with MPP (for 1 hr) followed by ICI.
After 48 hrs, PRL released into the CM was determined by the
sensitive Nb2 bioassay. (Fig. 3C) clearly shows that both ICI and
MPP independently inhibit PRL release from GH3 cells. Pretreat-
ment with MPP did not lead to blockade or augmentation of the
inhibitory effects of ICI on PRL release. We have previously shown
that the presence of ICI in the CM, at the dilutions used in the Nb2
assay, does not directly affect the proliferation of Nb2 cells [20]. To
verify that the observed MPP-induced decrease in PRL released
(Fig. 3C) was not due to its direct effect on Nb2 cells, we examined
the responsiveness of Nb2 cells to rat PRL in the presence and
absence of MPP. Our results (Fig. 3D) show MPP had no significant
effect on Nb2 cell proliferation in response to PRL.
Since both ICI and MPP suppressed prl expression, we next
questioned whether either compound suppresses ERE-mediated
transcriptional activity. For that, GH3 cells were transfected with
ERE-Luc reporter plasmid, and the ability of ICI and MPP to
suppress ERE transcriptional activity were evaluated. Fig. 4
demonstrates that Both ICI and MPP suppress ERE transcrip-
tional activity in a dose dependent manner, with a significant
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At the 10 nM concentration, both ICI (89.4% inhibition) and
MPP (75% inhibition) robustly suppressed ERE activity.
Discussion
Work from our laboratory as well as others have established a
role for ER in mediating lactotroph proliferation and PRL
expression, both in the presence and absence of E2. We have
previously shown that, even in the absence of E2, the ‘‘pure’’ anti-
estrogen ICI caused a rapid and robust degradation of ERa,
leading to inhibition of cell proliferation. We also demonstrated
that although Tam and Ral failed to significantly inhibit
lactotroph proliferation, like ICI, they are potent inhibitors of
PRL release from GH3 cells [20]. These studies lead us to
hypothesize that differential biological outcomes can be expected,
depending upon the ability of the anti-estrogen to degrade ERa.
Our results show that ICI induces proteasome-mediated
degradation of ERa in GH3 cells which was reversed by the
broad spectrum proteasome inhibitor MG132 (Fig. 1). The ability
of ICI to degrade ER via the proteasome is consistent with
previous reports in a variety of cell types [2,4]. We next questioned
whether preventing ICI-induced ERa degradation limits its
growth inhibitory effect on GH3 cells. A simple approach would
have been to block the ICI-induced ERa degradation with
MG132 (Fig. 1), and then assess its effect on cell proliferation.
However, we (data not shown) and others have shown that
prolonged use of proteasome inhibitors results in apoptosis in
lactotrophs [23]. We further explored this issue by comparing the
effects of MPP, a highly specific ERa antagonist that does not
degrade ERa [21,22]. Unlike ICI, which has a rapid and robust
effect on ERa degradation, MPP had no effect on ERa
degradation. Compared to ICI, MPP by itself was ineffective at
inhibiting GH3 cell proliferation. Supporting the above conclusion
were the results of the anchorage-independent growth assay as well
as clonogenic property of GH3 cells. While ICI completely
blocked colony formation, MPP had no significant effect. In
addition, preincubation of GH3 cells with 10-fold excess MPP,
Figure 1. Differential effects of ERa antagonist on cell proliferation and ERa degradation. A] GH3 cells were treated with either vehicle, ICI
(10 nM) or MPP (100 nM) for 5 days. Cell lysates were subjected to western blotting with an anti-ERa Ab (top panel). Equal loading was verified by
using the anti-actin Ab (lower panel). Results shown are from a single experiment and it is a representative of 3 independent experiments yielding
similar results. B] GH3 cells were treated either with 10 nM ICI for 1 hr, or pretreated with a broad-spectrum proteosome inhibitor MG132 (10 mM) for
1 hr, followed by ICI for 1 hr. Western blotting using anti-ERa Ab (Upper Panel), or anti-actin Ab (Lower Panel), was performed. Data is from a single
experiment and is representative of 2 independent experiments yielding similar results. C] GH3 cells were treated with either vehicle or ICI (0.001,
0.01, 0.1, 1, 10 and 100 nM) or MPP (0.001, 0.01, 0.1, 1, 10 and 100 nM) for 5 days, and cell proliferation was determined as described in the materials
and methods. Data is expressed as % of Control and it is the mean 6 SEM of 3 separate experiments. * indicates significant differences from control
(p,0.05). D] GH3 cells were treated with either vehicle, ICI (1 and 10 nM) or pretreated with MPP (100 nM for 1 hr) followed by treatment with ICI (1
and 10 nM) for 5 days. Cell proliferation was determined, and data is expressed as optical density, and it is the mean 6 SEM of 4–6 determinations
from a single experiment, which is a representative of 3 separate experiments with similar results. * designates significant differences from control
(p,0.05).
doi:10.1371/journal.pone.0010060.g001
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inability of MPP to suppress cell proliferation as well as anchorage
independent growth of GH3 cells was not due to its ineffectiveness,
since both ICI and MPP were effective at blocking ERE activity in
reporter gene assays (Fig. 4). Further, this differential effect of ICI
and MPP were observed in two other rat lactotroph cell lines (data
not shown). Taken together, we conclude that in the absence of E2
occupation of ERa by an antagonist is not sufficient to inhibit
lactotroph proliferation. Instead, ERa degradation must follow
upon antagonist occupation of the receptor.
While both MPP and ICI are competitive inhibitors of ligand
binding to ERa, it could be hypothesized that their differential
effects on cell proliferation are due to their interaction with
different pools of ERa. Although both our work (unpublished
observations) as well as work from other laboratories have
demonstrated the presence of nuclear as well as extra-nuclear
ERa in GH3 cells, it is unlikely that ICI and MPP target different
pools of ERa. This is based on our observations that excess MPP
effectively blocks the ICI induced inhibition of cell proliferation.
An alternate mechanism which could explain the differential
growth suppressive effects of ICI and MPP, is an involvement of
non-genomic/non-classical signaling mechanisms activated by
anti-estrogen-occupied ER. Indeed, ICI-mediated Erk1/2 activa-
tion appears to be critical for growth modulation in immature
cerebellar neurons [24]. Our preliminary results demonstrate that
ICI induced growth suppression of pituitary lactotrophs is
accompanied with decrease in cyclin D3 expression and
phosphorylation of Rb (unpublished observations). These results
are consistent with a previous study demonstrating a decrease in
cyclin D3 levels in response to ICI treatment in PR1 pituitary
lactotrophs [18]. Future studies will examine whether ICI-
mediated growth suppression is due to modulation of a non-
Figure 2. ICI 182780 but not MPP inhibits anchorage independent growth of GH3 cells. GH3 cells were cultured on soft agar in complete
medium containing ICI (10 nM) or (MPP 10 nM) as described in the materials and methods. A] Bright field microscopy shows GH3 cell colonies in soft
agar. B] Quantitative analysis of GH3 cell colonies in soft agar following anti-estrogen treatment. Colonies were counted in at least 3 independent
fields. Data is calculated as % of control and it is the mean 6 SEM of 4 separate experiments. * indicates significant differences from control (p,0.05).
doi:10.1371/journal.pone.0010060.g002
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expression and decreased phosphorylation of Rb.
We next explored the role of ERa degradation on PRL
production and release. The use of a reporter assay, western blotting
for intracellular PRL levels, and Nb2 assay for secreted PRL we
found that both ICI and MPP are equally effective at suppressing
PRL gene expression (Fig. 3B), decreased intracellular PRL (Fig. 3A),
as well as decreased release of PRL from GH3 cells into CM
(Fig. 3C). When GH3 cells were preincubated with a 10 -fold excess
of MPP, MPP failed to block the decreased expression of prl,
intracellular levels of PRL as well as the amount of PRL released into
the CM. These results indicate that occupation, and not degradation
of ERa, is sufficient to inhibit prl expression, and subsequently, its
production and release from GH3 cells. Since both ICI and MPP
were effective at suppressing prl expression, we examined whether
either compound inhibits ERE-mediated transcriptional activity. At
the 10 nM levels, both ICI and MPP inhibited ERE activity by more
than 75%. However, at 10 nM levels, MPP did not have any
significant effect on cell proliferation or ERa degradation. This
suggests that suppression of ERE transactivation is not the underlying
mechanism by which ICI inhibits cell proliferation.
Taken together our results indicate that in pituitary lactotrophs,
an ERa degrading antagonist such as ICI, but not an ERa
occupying antagonist such as MPP, initiates a signal cascade that
inhibits cell proliferation. On the other hand, occupation of ERa
by either type of antagonist is sufficient for inhibiting prl expression
and release. Anti-estrogens have been proposed as a class of novel
therapeutics for suppressing prolactionomas. Therefore, a com-
plete understanding of their differential effects on the lactotrophs
could help in the development of more effective therapeutics.
Figure 3. MPP and ICI 182780 inhibit PRL production and release. A] GH3 cells were treated with either vehicle, or ICI (10 nM), or MPP
(100 nM) or ICI + MPP for 5 days and cell lysates were subjected to western blotting using anti-PRL Ab (top panel) or anti-b tubulin Ab (bottom panel).
Data presented is from a single experiment and is representative of 3 separate experiments yielding similar results. B] GH3 cells, transiently co-
transfected with PRL-Luc and control reporter gene, were treated with either vehicle, or ICI (10 nM), or MPP (10 nM) for 24 hrs, and normalized
luciferase activity was determined. Data is calculated as fold change over control (arbitrary value of 1). Each value is the mean 6SEM of 3 separate
experiments each performed in triplicates. * indicates significant difference from control, (p,0.05). C] GH3 cells were treated for 5 days with either
vehicle, or ICI (10 nM), or MPP (100 nM) or ICI + MPP and the amount of PRL released into the CM was quantified by the Nb2 bioassay and is
expressed as mg PRL/mg protein. Each value is the mean 6SEM of 3 determinations from a single experiment, which is representative of 3 separate
experiments. * indicates significant difference from control (p,0.05). D] Nb2 cells were incubated with rPRL or rPRL in presence of MPP, and Nb2 cell
proliferation at the end of 3 days was determined by the MTT assay. Data is expressed as optical density, and it is the mean 6 SEM of 3
determinations from a single experiment, which is a representative of 3 separate experiments with similar results.
doi:10.1371/journal.pone.0010060.g003
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Chemicals and reagents
ICI 182780 and the ERa specific antagonist 4,49,40-(4-Propyl-
[1H] pyrazole-1,3,5-triyl) trisphenol (MPP), were purchased from
Tocris (Ellisville, MO). MG 132 was purchased from Calbiochem/
EMD Chemicals. Inc. (La Jolla, CA).
Cell culture
GH3 cells were purchased from ATCC (Manassas, VA) and
maintained in DMEM:F12 50:50 mix (Mediatech, Herndon, VA)
containing 10% FBS(Gibco/Invitrogen) and 5 U/ml Penicillin/
5 mg/ml Streptomycin (Pen/Strep).
Assessment of cell proliferation
GH3 cells in log phase were seeded at 20,000–30,000 cells/well in
DMEM:F12 (50:50) phenol red -free medium containing ITS
(insulin, transferrin, selenious acid) premix (BD Biosciences, San Jose,
CA) and Pen/Strep. Next day, cells were treated as indicated in
plating medium. Cell proliferation was quantitated using MTT assay
as described [20]. Briefly, 125 mg/well of MTT (3-[4,5-dimethylthia-
zole-2-yl] -2,5-diphenyltetrazolium bromide (Sigma) was added to
the treatment wells, and 2 hrs later, 100 ml of developer solution
(50% v/v DMF; 20% w/v SDS; 0.24% v/v glacial acetic acid;
60 mM sodium acetate) was added. Optical density at 570 nm was
determined. Data are presented as optical density or as percent of
vehicle (DMSO) control. We have recently shown that the MTT
assay is in excellent agreement with BrdU incorporation assay in
determining cell proliferation or inhibition in GH3 cells [20].
Luciferase reporter assays
After seeding, GH3 cells were cultured for 24 hrs, followed by
transient co-transfection with 0.8 mg of the 2.5 Kb rat PRL pA3
PRL/luc plasmid [25]; (a gift from Dr. A. Gutierrez-Hartman,
Denver, CO); or p3X ERE-luc reporter plasmid (gifted from Dr.
R. Bigsby, Indianapolis, IN); together with the control pGL4.70
[hRLuc] Renilla plasmid (Promega, Madison, WI), using Lipo-
fectamine 2000 (Invitrogen). Cells were washed and the medium
was replaced with plating medium containing the indicated
treatments. After treatments, cells were lysed and luciferase
activity was determined using the dual luciferase assay kit
(Promega, Madison, WI). Fold change in luciferase activity was
calculated after normalization to renilla.
Anchorage independent growth in soft agar
Anchorage independent growth was determined as described
[26]. Briefly, after pouring the base agar (0.6%) layer, the agar was
allowed to set. GH3 cells (1.5610
5 cells/well, in a 6 well plate) in
2X complete medium (containing either vehicle, ICI 10 nM, or
MPP 10 nM) were mixed with 0.3% agar and layered on the
bottom gelled layer of agar. Medium (containing ICI/MPP) was
changed every 3–4 days, and colony formation was determined by
counting the number of colonies using phase-contrast microscopy.
Western blotting
After treatment cell lysates were harvested as described [20].
Equal amounts of proteins (25–90 mg) were subjected to
electrophoresis on 7–12% SDS-PAGE gels. Fractionated proteins
were electrophoretically transferred onto PVDF membranes.
Incubation of membranes with primary antibodies was done at
4uC o/n. Incubation of membranes with secondary antibodies was
done at room temperature for 1 hr, and proteins detected by
enhanced chemiluminescence reagents (Pierce), as suggested in the
manufacturers protocol.
Nb2 Bioassay for quantitating PRL release
PRL concentrations in conditioned media (CM) were deter-
mined using a bioassay as described [20]. Briefly, after overnight
starvation, Nb2 cells were cultured for 72 hr with either rPRL
standard, amniotic fluid (1:1000) serving as an internal control, or
with CM aliquots from GH3 cells. After 3 days, Nb2 cell number
was determined by the MTT assay as above. The amount of PRL
secreted by GH3 cells was calculated from the standard curve and
is expressed as mg PRL/mg protein.
Data analysis
Statistical significance was determined using Student’s t test, a
value of p,0.05 was considered significant.
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